{"filings":[{"id":650037,"accession_number":"0001493152-26-025171","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-05-26T12:30:22+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.","event_type":"regulatory","confidence":"high","bullets":["Israeli Ministry of Health's AMAR Division grants marketing clearance for LIBERTY Endovascular Robotic System in Israel.","First regulatory approval outside the U.S.; enables Free Sale Certificate for submissions in other jurisdictions.","Company targets CE Mark certification by end of 2026 for EU market expansion.","System adopted by multiple U.S. accounts in GA, FL, NY, MA, MI, NC.","Advanced discussions underway to expedite commercialization in Israel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":"2026-05-26","daily_digest_url":"/daily/2026-05-26","daily_digest_rank":5},{"id":460596,"accession_number":"0001493152-26-023493","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-05-15T16:03:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical to host May 18 call correcting misrepresentations in third-party article; LIBERTY users to join","event_type":"other_material","confidence":"high","bullets":["Conference call on Monday, May 18 at 3 PM ET to address recent unaffiliated third-party article's misleading statements.","Dr. Charles Briggs (LIBERTY user at Tampa General) will dispute claims attributed to him in the article.","Dr. Zachary Bercu, first LIBERTY user at Emory, will discuss real-world experience with the system.","Wall Street firm published research report refuting assertions made in the same third-party article."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78163,"accession_number":"0001493152-26-022886","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-05-14T12:30:25+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical records first revenue from LIBERTY; Q2 revenue already exceeds Q1","event_type":"other_material","confidence":"medium","bullets":["Recorded revenue from limited market release of LIBERTY System in Q1 2026; transitioned to full market release in Q2.","Q2 revenue mid-way through quarter already exceeds total Q1 revenue; accounts more than doubled since LMR ended.","Hospitals in six states (GA, FL, NY, MI, MA, NC) have adopted the system; Boston now has multiple accounts.","First robotic procedures include PAE for BPH, GAE for knee pain, and Y-90 radioembolization for liver cancer.","Growth supported by updated occupational radiation guidelines from nine medical societies including AMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99422,"accession_number":"0001493152-26-021231","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical's LIBERTY robotic system adopted by multiple accounts, including pivotal trial sites","event_type":"other_material","confidence":"high","bullets":["LIBERTY Endovascular Robotic System won accounts in key U.S. territories, including two ACCESS-PVI trial sites.","Company to attend GEST conference in NYC from May 14-17, 2026 to expand commercial footprint.","Alon Tamir appointed VP of Sales, EMEA to lead international commercialization.","CEO cites 'strong tailwind post SIR' and expects sustained momentum through peer-to-peer communication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99421,"accession_number":"0001493152-26-019775","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical appoints Alon Tamir VP Sales EMEA, targets CE mark by end of 2026","event_type":"leadership","confidence":"high","bullets":["Alon Tamir named Vice President of Sales for Europe, Middle East and Asia (EMEA) to lead international expansion.","Company expects CE mark approval by end of 2026; leveraging FDA clearance received September 2025.","Europe has approximately 2.3 million peripheral endovascular procedures annually, comparable to U.S. market size.","LIBERTY Endovascular Robotic System is in full market release in the U.S. after limited market release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99420,"accession_number":"0001493152-26-018453","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical highlights updated SIR/CIRSE guidelines strengthening LIBERTY system position","event_type":"other_material","confidence":"high","bullets":["Updated joint guidelines from SIR and CIRSE cover radiation exposure and musculoskeletal risks for interventional radiology staff.","At least nine medical societies endorse the guidelines, including AMA, SCAI, ACC, and more.","AMA adopted a policy in late 2025 to strengthen protections for healthcare professionals against occupational radiation exposure.","LIBERTY system's remote operation aims to reduce radiation exposure and physical strain for physicians."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99419,"accession_number":"0001493152-26-016484","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical to highlight LIBERTY Endovascular Robotic System full market release at Needham Conference","event_type":"other_material","confidence":"high","bullets":["CEO Harel Gadot will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 10:15 a.m. ET.","The LIBERTY Endovascular Robotic System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.","Microbot completed the limited market release and commenced full market release of LIBERTY in the U.S. at the SIR Annual Scientific Meeting.","Senior executives will provide an overview of strategic positioning, growth opportunities, and market needs including physician radiation risks and physical strain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99418,"accession_number":"0001493152-26-016293","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical launches full market release of LIBERTY robotic system after successful limited release","event_type":"other_material","confidence":"high","bullets":["LIBERTY adopted by multiple healthcare systems including Emory Healthcare and Tampa General Hospital during limited market release.","Used commercially across procedures: PAE, UFE, GAE, Y90 mapping/deliveries, peripheral interventions.","Full market release commenced at SIR Annual Scientific Meeting in Toronto (April 11-15, 2026).","Sales footprint expanded from 4 to 8 territories; target of 12 U.S. territories by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99417,"accession_number":"0001493152-26-016198","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Microbot Medical files prospectus supplement for existing ATM program with H.C. Wainwright","event_type":"other_material","confidence":"high","bullets":["Company files prospectus supplement for ATM program with Wainwright; aggregate offering price up to $39,230,691.","Sales Agreement originally dated June 10, 2021, amended July 1, 2024.","Opinion of Mintz Levin regarding validity of ATM Shares filed as Exhibit 5.1.","No actual sales reported; program previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115410,"accession_number":"0001493152-26-012812","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System","event_type":"other_material","confidence":"high","bullets":["World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.","First robotic Y-90 radioembolization mapping for liver cancer completed using the same system.","LIBERTY is FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.","Limited Market Release started November 2025; Full Market Release planned for April 2026 at SIR conference.","BPH affects approximately 40 million men in the U.S.; LIBERTY aims to become standard of care for PAE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115409,"accession_number":"0001493152-26-012281","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical's LIBERTY pivotal study published in JVIR; full market launch in April 2026","event_type":"other_material","confidence":"high","bullets":["ACCESS-PVI study published in JVIR, a top radiology journal, after independent peer review.","LIBERTY received FDA clearance in Sep 2025; limited market release started late 2025.","Full commercial launch planned at SIR conference in April 2026 to expand adoption.","Dr. Francois Cornelis, first author, was Lead PI for the multicenter feasibility study.","LIBERTY is first FDA-cleared single-use robotic system for peripheral endovascular procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115408,"accession_number":"0001493152-26-010446","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical to present at Roth Conference; full LIBERTY market release on track for April 2026","event_type":"other_material","confidence":"high","bullets":["CEO Harel Gadot to present fireside Q&A at Roth Annual Growth Conference on March 23, 2026 at 4:00 pm PT.","Limited market release of LIBERTY Endovascular Robotic System began in late 2025; full market release targeted at SIR conference in April 2026.","LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.","Company highlights multi-site customer traction and procedural diversity during limited release phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115407,"accession_number":"0001493152-26-009454","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical to present at Oppenheimer Healthcare Conference on March 19, 2026","event_type":"other","confidence":"high","bullets":["CEO Harel Gadot will present live at 8:40am ET on March 19, highlighting LIBERTY system milestones.","First time invited to this conference; company cites growing market interest.","Full market release of LIBERTY planned at SIR conference in April 2026.","CFO Rachel Vaknin and VP Earl Adamy available for one-on-one meetings on March 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115406,"accession_number":"0001493152-26-008782","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical praises new AMA radiation policy; cites 92% cut with LIBERTY robot","event_type":"other_material","confidence":"high","bullets":["AMA adopted new policy in late 2025 to strengthen protections from ionizing radiation; Microbot commends the move.","LIBERTY system demonstrated 92% relative reduction in radiation exposure in ACCESS-PVI Study.","LIBERTY is FDA-cleared, single-use, remotely operated, designed for precise navigation with reduced radiation.","Limited Market Release began late 2025; Full Market Release planned for April 2026 at SIR conference.","CEO Harel Gadot says LIBERTY can address staffing shortages and improve care for patients and providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115405,"accession_number":"0001493152-26-008658","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical confirms no business disruption amid Middle East events, progresses LIBERTY commercial launch","event_type":"other_material","confidence":"high","bullets":["No business disruption in USA or Israel; all personnel operational, lead manufacturing partner fully functional.","LIBERTY system received FDA clearance; limited market release began late 2025; full market release at SIR April 2026.","Hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research (HEOR) for commercial expansion.","Sufficient U.S. inventory maintained; building additional stock via third-party logistics partner for anticipated demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115404,"accession_number":"0001493152-26-007900","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Microbot Medical raises executive salaries, bonuses; CEO gets $140k special bonus","event_type":"leadership","confidence":"high","bullets":["CTO Simon Sharon base salary increased to NIS 1,008,000; CFO Rachel Vaknin to NIS 756,000, retroactive Jan 1, 2026.","Maximum annual bonus for CTO, CFO, and CMO raised to 50% of base salary, effective for 2026 fiscal year.","CEO Harel Gadot authorized a special bonus of approximately $140,000 in addition to existing agreement.","Base salaries subject to annual review by Compensation Committee; no further amendment required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115403,"accession_number":"0001493152-26-007827","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tampa General Hospital first in Florida to adopt Microbot's LIBERTY robotic system","event_type":"other_material","confidence":"high","bullets":["Tampa General Hospital (TGH) becomes first Florida health system to adopt LIBERTY Endovascular Robotic System after FDA 510(k) clearance.","LIBERTY is the only FDA-cleared single-use remotely operated robotic system for peripheral endovascular procedures.","U.S. peripheral endovascular procedures market approximately 2.5 million annually, representing significant commercial opportunity.","Limited market release began late 2025; full market release planned at SIR conference in April 2026.","CEO Harel Gadot cites TGH's innovation culture as endorsement of LIBERTY's value and market relevance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115402,"accession_number":"0001493152-26-007429","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical CEO to speak at SAGES NBT Innovation Weekend panel on endovascular robotics","event_type":"other","confidence":"high","bullets":["CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit (Feb 19-21, 2026 in Houston, TX).","Panel titled 'Endovascular Therapeutics: AI and Robotics' to highlight the LIBERTY Endovascular Robotic System.","LIBERTY is FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.","Limited market release commenced in late 2025; full market release planned at SIR conference in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115401,"accession_number":"0001493152-26-006310","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical's LIBERTY system featured at ISET; gains commercial traction in limited market release","event_type":"other_material","confidence":"medium","bullets":["LIBERTY Endovascular Robotic System highlighted at ISET conference Feb 9-12, 2026 in Miami Beach.","LIBERTY is only FDA-cleared single-use endovascular robotic system; featured in Town Hall session on future of robotics.","Limited market release commenced late 2025; full market release planned at SIR conference April 2026.","System used across multiple hospitals for wide range of procedure types including complex cases; interest from multiple specialties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115400,"accession_number":"0001493152-26-005206","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot attending SIO conference; LIBERTY limited release ongoing, full release planned April 2026","event_type":"other_material","confidence":"high","bullets":["Microbot Medical (MBOT) attending Society of Interventional Oncology conference Feb 4-8, 2026 in Savannah, GA.","Company will share physician experiences with LIBERTY Endovascular Robotic System from limited market release.","First commercial exhibition of LIBERTY since limited market release began in late 2025.","Full market release of LIBERTY planned for April 2026 at SIR conference.","LIBERTY is FDA-cleared, single-use, remotely operated robotic system for peripheral procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115399,"accession_number":"0001493152-26-001234","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Microbot Medical reaffirms 2025 achievements, outlines 2026 milestones including Full Market Release in Q2","event_type":"other","confidence":"high","bullets":["Received FDA 510(k) clearance for LIBERTY, first single-use remotely operated robotic system for peripheral endovascular procedures.","Emory University Hospital became first adopter of LIBERTY under Limited Market Release; 100% robotic navigation success in ACCESS PVI trial.","Full Market Release of LIBERTY planned for Q2 2026, coinciding with SIR conference.","Targeting 2.5 million annual peripheral endovascular procedures in U.S.; building pipeline for cardiology and neurovascular spaces.","Expanded IP portfolio to 20 patents granted, 52 applications pending; balance sheet bolstered with non-dilutive grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131825,"accession_number":"0001493152-25-025069","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical's LIBERTY robotic system adopted by Emory University Hospital as first hospital worldwide","event_type":"other_material","confidence":"high","bullets":["Emory University Hospital in Atlanta is first hospital globally to adopt Microbot's LIBERTY Endovascular Robotic System for patient care.","Microbot and Emory collaborate to establish an Endovascular Robotics Program in interventional radiology.","LIBERTY is FDA-cleared, single-use, remotely operated robotic system designed to reduce radiation exposure and physical strain.","Company launched limited market release weeks ago; full market release expected at SIR conference in April 2026.","Emory will use LIBERTY for procedures including liver tumor embolization, prostate artery embolization, and uterine fibroid embolization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131824,"accession_number":"0001493152-25-020815","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical launches limited U.S. commercial release of LIBERTY robotic system","event_type":"other_material","confidence":"high","bullets":["LIBERTY Endovascular Robotic System now commercially available in U.S. on a limited basis after FDA 510(k) clearance in September 2025.","Limited Market Release (LMR) targets high procedure volume regions with existing preliminary demand; Full Market Release (FMR) planned for April 2026 at Society of Interventional Radiology meeting.","Company has hired core commercial team and secured third-party logistics partner to support the launch.","CEO Harel Gadot states the launch marks entry into commercialization phase, building a new robotic category with single-use system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131823,"accession_number":"0001493152-25-018260","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical to debut LIBERTY System at CIO meeting; hires commercial team","event_type":"other_material","confidence":"high","bullets":["First commercial exhibition of LIBERTY Endovascular Robotic System at CIO symposium in Miami, Oct 17-19, 2025.","Completed hiring of commercial leadership: Justin Bourne (Regional Sales Dir), Dani Kulp (Sales Training Dir), Xiomara Ortiz (Marketing Comm Mgr).","Limited market launch of LIBERTY System remains on track for Q4 2025.","FDA 510(k) clearance received in early September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131822,"accession_number":"0001493152-25-017941","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot partners with US logistics provider; LIBERTY launch on track for Q4 2025","event_type":"other_material","confidence":"high","bullets":["Partnered with an experienced medtech 3PL company for inventory management and order fulfillment.","Limited market release of FDA-cleared LIBERTY Endovascular Robotic System expected Q4 2025.","Broader commercial launch targeted for April 2026 at the Society of Interventional Radiology conference.","Michal Ahuvia, Director of Operations, says logistics support strengthens go-to-market efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131821,"accession_number":"0001493152-25-017212","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Microbot Medical completes final PIO exercise closing, raising $29.2M initial gross proceeds","event_type":"other_material","confidence":"high","bullets":["Three closings: $25.2M (first), $1.2M (second), $2.8M (third) – total $29.2M gross proceeds before fees.","New series J preferred investment options issued; exercise price $4.50, exercisable after 6 months, 2-year term.","Potential additional ~$63M if series J options fully exercised on a cash basis (no guarantee).","Net proceeds to fund development/commercialization of LIBERTY Robotic System and for working capital.","H.C. Wainwright & Co. served as exclusive placement agent for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131820,"accession_number":"0001493152-25-016866","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Microbot Medical issues stock and options in two unregistered transactions","event_type":"other_material","confidence":"high","bullets":["Holder exercised 600,000 series H PIOs at $2.10/share, receiving 600,000 shares and new series J PIOs.","Remaining 1,324,488 series H PIOs expected to be exercised in additional closings by October 15, 2025.","Issued 30,000 Wainwright PIOs to H.C. Wainwright as placement agent compensation.","On September 23, issued 374,167 shares upon PA Options exercise, generating ~$896,000 gross proceeds.","All issuances rely on Section 4(a)(2) exemption; securities not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131819,"accession_number":"0001493152-25-016484","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical receives first Japanese patent for LIBERTY System; also patents in US, China, Israel","event_type":"other_material","confidence":"high","bullets":["Japanese Patent Office granted first Japan patent covering core LIBERTY System technology for compact robotic surgical tool.","Company also received patents in the US, China, and Israel over the past 90 days, broadening global IP portfolio.","FDA marketing clearance for LIBERTY System announced on Sept 8, 2025; commercial launch targeting ~2.5M annual US peripheral procedures.","Management evaluating global markets that accept FDA clearance, with Japan seen as strategically important."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148418,"accession_number":"0001493152-25-014557","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical CEO to Discuss LIBERTY FDA Clearance and Commercialization on Benzinga Interview Sept 24","event_type":"other_material","confidence":"high","bullets":["CEO Harel Gadot will be interviewed on Benzinga All Access at 10:45am ET on September 24, 2025.","Discussion will cover recent FDA 510(k) clearance of the LIBERTY Endovascular Robotic System.","FDA clearance for LIBERTY was announced on September 8, 2025.","Company plans for U.S. commercialization of the peripheral endovascular system.","LIBERTY is described as the first single-use, remotely operated robotic solution for endovascular procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148417,"accession_number":"0001493152-25-014263","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Microbot Medical awards special cash bonuses: CEO $158K, CTO $64K, $32.5K to CEO Vaknin; board $30-45K","event_type":"other","confidence":"high","bullets":["CEO/Harel Gadot gets $158,115; CTO Simon Sharon ~$64,200; CEO Rachel Vaknin ~$32,500 for prior salary waivers in 2023 restructuring.","Non-management directors each receive one-time cash payments of $30,000–$45,000, approved by the Compensation Committee.","Bonuses partially compensate executives who waived 30–50% of prorated 2023 base salary under May 2023 cost reduction plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148416,"accession_number":"0001493152-25-013743","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Microbot Medical raises $25.2M in first close of PIO exercise; potential total $92.2M","event_type":"other_material","confidence":"high","bullets":["First closing on Sep 16 generated ~$25.2M gross; second closing expected by Oct 15 for ~$4M.","Issued new Series J PIOs to purchase up to 13.99M shares at $4.50/share (exercise starts 6 mo, 2-yr term).","Existing PIOs exercised at $1.50-$2.13/share; new PIOs at $4.50/share, providing potential $63M if fully cashed.","Proceeds to be used for LIBERTY Robotic System development, M&A, IP expansion, and working capital.","On Sep 8, 2025, issued 225k shares upon Series H PIO exercise for $472,500 gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148415,"accession_number":"0001641172-25-026942","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical releases updated investor presentation, presents at H.C. Wainwright conference","event_type":"other","confidence":"low","bullets":["Updated presentation materials released on September 9, 2025, available on company website.","CEO Harel Gadot presented live at H.C. Wainwright Annual Investor Conference in New York on Sept 9.","No specific financial or operational updates disclosed in the filing beyond the presentation release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148414,"accession_number":"0001641172-25-026815","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical receives FDA 510(k) clearance for LIBERTY Endovascular Robotic System","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance for LIBERTY System, first single-use remotely operated robotic system for peripheral endovascular procedures.","Pivotal study showed 100% robotic navigation success and zero device-related adverse events; 92% relative reduction in physician radiation exposure.","Plans to commence commercialization in Q4 2025; initial U.S. addressable market of ~2.5M peripheral vascular procedures annually.","CEO Harel Gadot to present at H.C. Wainwright Annual Investor Conference on Sept 9, 2025 at 9 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148413,"accession_number":"0001641172-25-025709","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Microbot Medical issues 4.06M shares on option exercises, raises ~$8.6M","event_type":"other_material","confidence":"high","bullets":["Issued 300,000 Series H option shares at $2.10 and 3,755,870 Series I option shares at $2.13.","Gross proceeds of approximately $8.6 million before placement agent fees and expenses.","Outstanding common stock now ~52.57 million shares as of August 27, 2025.","Shares issued under Section 4(a)(2) private placement exemption; registered for resale on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148412,"accession_number":"0001641172-25-025390","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Microbot Medical issues ~3M shares upon option exercises, raising ~$5.9M gross","event_type":"other_material","confidence":"high","bullets":["Issued 2,967,953 shares from Series E, G, H preferred investment options between Aug 11-25, 2025.","Exercise prices: $1.50 (Series E), $1.75 (Series G), $2.10 (Series H); aggregate proceeds ~$5.9M gross.","Also issued 47,218 shares upon exercise of incentive options by a former director.","Total outstanding common stock post-issuance approximately 48,513,892 shares as of Aug 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148411,"accession_number":"0001641172-25-024927","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical granted USPTO patent expanding LIBERTY system TAM to 6M+ US procedures","event_type":"other_material","confidence":"high","bullets":["Patent covers modular robotic system with interchangeable tool-receiver units attachable to base.","IP portfolio now: 12 patents granted globally, 57 patent applications pending.","Enables future adaptation for wider endovascular procedures; US TAM could grow from 2.5M to 6M+ annual procedures.","Company continues commercial readiness plans for LIBERTY system while awaiting FDA 510(k) clearance.","CEO Harel Gadot: near-term focus remains on peripheral market and commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148410,"accession_number":"0001641172-25-022151","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical raises ~$7.6M from option exercises, receives NIS 2.15M IIA grant","event_type":"other_material","confidence":"high","bullets":["Issued 4,344,286 shares at $1.75 upon exercise of Series G options, gross proceeds $7.6M.","Approved for non-dilutive grant of NIS 2.15M (~$630k) from Israel Innovation Authority.","Grant to enhance manufacturing capabilities for LIBERTY System as FDA clearance decision nears.","CFO states grant reflects high confidence in scaling manufacturing and meeting business objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148409,"accession_number":"0001641172-25-021486","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Microbot Medical issues 2.4M shares on warrant exercises, raising $4.2M","event_type":"other_material","confidence":"high","bullets":["Issued 2,395,715 shares of common stock upon exercise of Series G preferred investment options since July 17, 2025.","Exercise price was $1.75 per share, generating gross proceeds of approximately $4.2 million.","Shares were issued under Section 4(a)(2) exemption; resale registered on Form S-3 (333-284688).","Placement agent fees and expenses not yet deducted from the $4.2M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148408,"accession_number":"0001641172-25-020524","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical appoints Christina Bailey as VP of Sales ahead of LIBERTY launch","event_type":"leadership","confidence":"high","bullets":["Christina Bailey named VP of Sales; reports to CEO Harel Gadot.","Bailey brings 20 years med device experience at Boston Scientific, Abbott, Stryker, Intuitive Surgical, Endologix.","She is a two-time U.S. Olympian and gold medalist (1998 women's hockey).","Role includes building sales team to support anticipated launch of LIBERTY endovascular robotic system.","LIBERTY is an investigational device pending FDA 510(k) clearance, not yet for sale in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148407,"accession_number":"0001641172-25-020076","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Microbot Medical raises ~$3.0M via exercise of Series F and G options","event_type":"other_material","confidence":"high","bullets":["Issued 1,808,336 shares upon exercise of 1,025,000 Series G and 783,336 Series F options since June 18, 2025.","Series G options exercised at $1.75/share, generating ~$1.8M gross proceeds.","Series F options exercised at $1.50/share, generating ~$1.175M gross proceeds.","Shares registered for resale on Form S-3; issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148406,"accession_number":"0001641172-25-018098","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot to present at inaugural SRS Endovascular Robotics session; FDA 510(k) decision expected this quarter","event_type":"other_material","confidence":"high","bullets":["Participates in Society of Robotic Surgery annual meeting July 16-20 in Strasbourg, France.","CEO Harel Gadot to present overview of endovascular robotics market at panel on July 19.","Company strengthening sales & marketing infrastructure ahead of anticipated U.S. FDA 510(k) decision this quarter.","Liberty system remains investigational; not yet approved for sale in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167206,"accession_number":"0001641172-25-017053","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical added to Russell Microcap Index effective June 30, 2025","event_type":"other_material","confidence":"high","bullets":["Added to the Russell Microcap Index as of market open on June 30, 2025, with automatic inclusion in growth and value style indexes.","CEO Harel Gadot cited strong execution, ongoing FDA 510(k) submission for LIBERTY, and anticipated Q3 commercial launch.","Membership is based on market-cap rankings; Russell indexes serve as benchmarks for about $10.6 trillion in assets (June 2024).","Microbot Medical (MBOT) is a pre-commercial endovascular robotics developer; LIBERTY is pending FDA 510(k) clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167205,"accession_number":"0001641172-25-015345","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical granted Chinese patent; issues 1.48M shares for $2.22M","event_type":"other_material","confidence":"high","bullets":["China National IP Administration granted patent covering robotic manipulation of surgical tool handle.","LIBERTY System now has nine global patents granted and 59 patent applications pending.","Since May 13, 2025, issued 1.48M shares upon exercise of Series E/F options at $1.50, raising ~$2.22M gross.","Anticipated U.S. commercial launch of LIBERTY in Q3 2025, pending FDA 510(k) clearance, preparations accelerating.","Patent supports global IP strategy; China estimated ~2.9M peripheral endovascular procedures annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167204,"accession_number":"0001641172-25-014622","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Microbot Medical shareholders approve increase in authorized common shares to 120M; Series I options become exercisable","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 61M to 120M; total authorized shares now 121M (including 1M preferred).","Stockholders approved issuance of Series I options (12,206,578 shares at $2.13) and placement agent options (305,164 shares at $2.6625); now immediately exercisable.","Amendment to 2020 Omnibus Performance Award Plan approved, adding 2,591,019 authorized shares.","Class I directors elected: Harel Gadot, Martin Madden, Tal Wenderow; each received >3M votes for.","Brightman Almagor Zohar & Co. ratified as independent auditor for FY2025 with 13.2M votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167203,"accession_number":"0001641172-25-014242","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Microbot Medical expects FDA 510(k) decision for LIBERTY System in Q3 2025; hires sales ops head","event_type":"regulatory","confidence":"high","bullets":["Added Michael Lytle as head of Sales Operations & Analytics to strengthen pre-launch infrastructure.","FDA 510(k) decision now expected in Q3 2025, remaining within original review window.","Projected U.S. launch of LIBERTY Endovascular Robotic System remains on track for Q3 2025.","CEO Harel Gadot stated confidence in FDA process and commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167202,"accession_number":"0001641172-25-013719","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical selected for Russell Microcap Index inclusion effective June 27, 2025","event_type":"other_material","confidence":"high","bullets":["Announced preliminary addition to Russell Microcap Index published by FTSE Russell on May 23, 2025.","Index reconstitution effective after U.S. market close on June 27, 2025; trading begins June 30, 2025.","Membership based on market capitalization as of April 30, 2025; inclusion lasts one year.","Russell indexes serve as benchmark for approximately $10.6 trillion in assets as of June 2024.","Company is developer of LIBERTY Endovascular Robotic System, currently pre-commercial stage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167201,"accession_number":"0001641172-25-007887","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Microbot Medical posts updated presentation; no financial details in filing","event_type":"other_material","confidence":"low","bullets":["Released updated investor presentation on April 30, 2025, available on company website.","Presentation furnished as Exhibit 99.1; no specific financial or operational data disclosed.","Filing is procedural; confidence low because presentation content not provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167200,"accession_number":"0001641172-25-005780","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Microbot Medical adds VP Marketing, Director HR, raises ~$2.3M from option exercises ahead of FDA decision","event_type":"other_material","confidence":"high","bullets":["Issued 1,533,336 common shares upon exercise of Series F and Series E preferred investment options at $1.50/share, generating ~$2.3M gross proceeds.","Appointed Allison Rosefort as VP of Marketing; she brings 15+ years MedTech marketing experience, most recently at Topcon Healthcare.","Appointed Lisa Dobbins as Director, Human Resources; she previously was HR Business Partner at Integra LifeSciences.","Company preparing for U.S. commercial launch of LIBERTY Endovascular Robotic System ahead of expected FDA decision in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167199,"accession_number":"0001641172-25-005289","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Microbot moves two proposals from cancelled special meeting to June 10 annual meeting","event_type":"other","confidence":"high","bullets":["Company could not obtain quorum for April 11 special meeting; cancelled it instead of adjourning.","Two proposals originally for the special meeting are now included in the preliminary proxy for June 10 annual meeting.","Preliminary proxy statement on Schedule 14A filed with SEC on April 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167198,"accession_number":"0001641172-25-004707","cik":883975,"company_name":"Microbot Medical Inc.","ticker":"MBOT","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["3.03","5.03","5.08","9.01"],"status":"ready","headline":"Microbot Medical reduces stockholder quorum to one-third; sets June 10, 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Board approved bylaw amendment reducing quorum from majority to one-third of votes entitled to be cast, effective immediately.","2025 annual meeting scheduled on or about June 10, 2025; record date April 15, 2025.","Deadline for Rule 14a-8 proposals and director nominations is April 28, 2025.","Change in meeting date (more than 30 days from prior year's meeting) triggers new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-04-15T23:59:59+00:00|167198"}